Combined efficacy of sPGA with H. pylori antibody [11] and/or gastrin-17 [12,13] has been indicated for the prediction of gastric cancer [11] and CAG [12,13], and it is mainly used in Europe (as panel test). This evidence concerns the gene GAST and gastric cancer.